Apogee is led by CEO Michael Henderson, who was previously the chief business officer of BridgeBio Pharma.

Source: https://medcitynews.com/2023/06/biotech-ipo-immunology-inflammation-eczema-atopic-dermatitis/

BBIO stock jumped 60% early this morning due to BridgeBio Pharma’s positive clinical results.

Source: https://investorplace.com/2023/03/why-is-bridgebio-pharma-bbio-stock-up-60-today/

For example, KKR & Co Inc invested in gene-therapy company BridgeBio Pharma Inc in an early-stage funding round in 2016, funded the company through its initial public offering in 2019, and continues to be its largest shareholder.

Source: https://gazette.com/news/us-world/private-equity-acquires-a-taste-for-drug-development/article_581329a7-f394-5c45-aa25-2599a5c7a2b3.html

Pinnacle Associates Ltd. reduced its holdings in BridgeBio Pharma, Inc. () by 2.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission.

Source: https://www.etfdailynews.com/2023/04/08/pinnacle-associates-ltd-has-390000-position-in-bridgebio-pharma-inc-nasdaqbbio/

SVB Leerink cut their target price on shares of BridgeBio Pharma from $23.00 to $19.00 and set an “outperform” rating for the company in a report on Monday, January 23rd.

Source: https://www.dailypolitical.com/2023/02/06/bridgebio-pharma-inc-nasdaqbbio-ceo-neil-kumar-sells-120000-shares.html